Minireviews
Copyright ©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Feb 14, 2019; 25(6): 659-671
Published online Feb 14, 2019. doi: 10.3748/wjg.v25.i6.659
Cancer risk in primary sclerosing cholangitis: Epidemiology, prevention, and surveillance strategies
Brian M Fung, Keith D Lindor, James H Tabibian
Brian M Fung, UCLA-Olive View Internal Medicine Residency Program, Olive View-UCLA Medical Center, Sylmar, CA 91342, United States
Keith D Lindor, Office of the University Provost, Arizona State University, Phoenix, AZ 85004, United States
James H Tabibian, Division of Gastroenterology, Department of Medicine, Olive View-UCLA Medical Center, Sylmar, CA 91342, United States
Author contributions: Tabibian JH and Fung BM reviewed the literature for relevant original studies and other content; Fung BM designed and/or formatted the figures; Tabibian JH and Lindor KD reviewed the figures; Fung BM drafted the manuscript; Tabibian JH and Lindor KD provided supervision; all authors provided critical input and approved of the manuscript.
Conflict-of-interest statement: The authors have no financial disclosures or conflicts of interest.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: James H Tabibian, MD, PhD, Health Sciences Clinical Associate Professor, David Geffen School of Medicine at UCLA, Director of Endoscopy, Department of Medicine, Olive View-UCLA Medical Center, 14445 Olive View Drive, 2B-182, Sylmar, CA 91342, United States. jtabibian@dhs.lacounty.gov
Telephone: +1-747-2103205 Fax: +1-747-2104573
Received: October 30, 2018
Peer-review started: November 1, 2018
First decision: November 29, 2018
Revised: January 10, 2019
Accepted: January 14, 2019
Article in press: January 15, 2019
Published online: February 14, 2019
Processing time: 109 Days and 4.6 Hours
Abstract

Primary sclerosing cholangitis (PSC) is a rare cholestatic liver disease characterized by progressive fibroinflammatory destruction of the intra- and/or extrahepatic biliary ducts. While its features and disease course can be variable, most patients with PSC have concurrent inflammatory bowel disease and will eventually develop liver cirrhosis and end-stage liver disease, with liver transplantation representing the only potentially curative option. Importantly, PSC is associated with a significantly increased risk of malignancy compared to the general population, mainly cholangiocarcinoma, gallbladder carcinoma, hepatocellular carcinoma, and colorectal cancer, with nearly 50% of deaths in patients with PSC being due to cancer. Therefore, robust surveillance strategies are needed, though uncertainty remains regarding how to best do so. In this review, we discuss the epidemiology, prevention, and surveillance of cancers in patients with PSC. Where evidence is limited, we present pragmatic approaches based on currently available data and expert opinion.

Keywords: Bile duct diseases; Cholangiocarcinoma; Gallbladder carcinoma; Hepatocellular carcinoma; Colorectal cancer; Chemoprotection; Inflammatory bowel disease

Core tip: Primary sclerosing cholangitis is a rare cholestatic liver disease characterized by progressive fibroinflammatory destruction of the bile ducts. It is associated with a significantly increased risk of malignancy over the general population, with nearly 50% of deaths in patients with primary sclerosing cholangitis caused by cancer, thus necessitating robust surveillance strategies. In this article, we provide a synopsis of the epidemiology, prevention, and surveillance of cancers in patients with primary sclerosing cholangitis.